The at-home kits were divvied up and picked up by 19 different school districts in Erie County for distribution.
Category: NEWS
Post
Access Bio, Inc. CareStart™ COVID-19 Detection Kits Efficacy in New SARS-CoV-2 Variant Omicron
Based on sequence analysis and Omicron recombinant protein test, Omicron variant does not have influence on the target region of CareStart™ COVID-19 Rapid and PCR Tests.
Post
ANNOUNCEMENT OF THE RECORD DATE FOR DETERMINING SHAREHOLDERS
In accordance with Article 16 (1) of the “Korean Depository Receipt Agreement” signed between Access Bio and Korea Securities Depository on March 11, 2013, the Record Date for determining shareholders in 2020 is December 31, 2020.
Post
CONCORDANCE HEALTHCARE SOLUTIONS AND NDC INK NATIONAL DISTRIBUTION AGREEMENTS
Major supply chain agreements will ensure broad access to rapid testing solutions for patients and healthcare providers across US
Post
CARESTART™ IGM/IGG ANTIBODY TEST GRANTED EUA AUTHORIZATION
Global Leader in Infectious Disease Diagnosis Receives FDA EUA for Serology Test Capable of Determining Subjects’ past COVID-19 Exposure and Immunoresponse within 10 Minutes
Post
GETTING TESTS WHERE THEY’RE NEEDED MOST
Access Bio was founded on the basic principle of cherishing life and health for all people. The company has emerged as a leader in the diagnosis of infectious diseases. Although it provides a comprehensive portfolio, Access Bio is known for its work against malaria, HIV, HPV, and now, COVID-19.
Post
IN PARTNERSHIP WITH THE GLOBAL GOOD
New rapid diagnostic test now available to research organizations for low parasitemia settings